Second medical use

Cholesterol-lowering drugs

UPC hears first main trial concerning second medical use

This week, the UPC heard its first hearing on the merits in a second medical use patent case. The dispute is part of ongoing litigation in various cou ...

26 February 2025 by Christina Schulze

10 September 2024 by Christina Schulze

Accord, Sanofi, chemo, Judicial Court Paris

Pharmaceuticals

Paris court revokes Sanofi cabazitaxel patent

Generic drug company Accord's nullity action has been successful. The Judicial Court of Paris has revoked the patent protecting Sanofi's chemotherapy ...

15 August 2022 by Konstanze Richter

Second medical use

Novartis faces new setback in French dispute over fingolimod

Novartis is currently fighting with various generic drug companies throughout Europe over a second medical use patent for fingolimod, so far with limi ...

2 June 2022 by Amy Sandys

Pharmaceuticals

Teva repels PI application in Neurim's fight against generics

The UK High Court has rejected an application by Neurim and Flynn against Teva for a preliminary injunction concerning an anti-insomnia drug patent. T ...

26 April 2022 by Konstanze Richter

The Netherlands

BarentsKrans and Mylan repel Novartis' bid for fingolimod PI

The District Court of The Hague has rejected Novartis' application for a preliminary injunction, meaning Mylan can market its generic drug containing ...

22 April 2022 by Amy Sandys

Licensing

Court deems Flynn exclusive licensee in Mylan insomnia drug battle

The Court of Appeal in London has ascertained that Flynn is an exclusive licensee of Neurim, overturning a first-instance decision from 2020. But the ...

28 October 2021 by Christina Schulze

Second medical use

Surprise success for Bayer blockbuster Xarelto at EPO

The EPO Boards of Appeal have reinstated the dosing patent for Bayer's thrombosis blockbuster drug, Xarelto. In the first instance, the patent was rev ...

8 June 2021 by Konstanze Richter

"Health insurance funds are condoning patent infringement”

Interview with Christian Stallberg: Effectively enforcing second medical use claims is difficult. In Germany, this is because of the complex interplay ...

8 June 2021 by Konstanze Richter

"Norway is an example of how to do things differently”

Interview with Dorian Immler: Originators like Bayer are not tapping the full potential of second medical use claims because of difficulties enforcing ...

8 June 2021 by Mathieu Klos

Dead end with no way out

Originators do not believe there is a Europe-wide solution to the urgent problem of off-label use of generic pharmaceuticals. The interests of those i ...

8 June 2021 by Konstanze Richter

Originators respond with individual strategies

When filing second medical use claims, the companies surveyed by JUVE Patent are satisfied with the European Patent Office. But creativity is called f ...

8 June 2021 by Mathieu Klos

Beloved problem child

Pharmaceutical research companies in Europe hold second medical use claims in high regard and are busy filing them at the European Patent Office. Thei ...

Multiple Sclerosis biosimilar

Wuesthoff and Bird & Bird pave way for MS drug licence deal

Sandoz will take over the global commercialisation for a proposed natalizumab biosimilar of Polpharma. The agreement was accompanied by successful att ...

12 September 2019 by Mathieu Klos

10 January 2019 by Konstanze Richter

Second medical use

AstraZeneca appeal rejected in generics-favourable decision

Second medical use is currently a hot topic in pharmaceutical patents. In the dispute over the breast cancer drug containing the active ingredient ful ...